Deuruxolitinib phosphate is under clinical development by Sun Pharmaceutical Industries and currently in Pre-Registration for Alopecia Areata. According to GlobalData, Pre-Registration drugs for Alopecia Areata does not have sufficient historical data to build an indication benchmark PTSR for Pre-Registration. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Deuruxolitinib phosphate LoA Report. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Deuruxolitinib phosphate overview
Deuruxolitinib phosphate (CTP-543, Deuterated Ruxolitinib) is under development for the treatment of moderate to severe alopecia areata. It is a deuterium-modified analog of ruxolitinib administered orally. It acts by targeting the Janus kinases (JAK1 and JAK2). It is developed based on the DCE (deuterated chemical entity) platform.
Sun Pharmaceutical Industries overview
Sun Pharmaceutical Industries (Sun Pharma) is a specialty pharmaceutical company that offers an array of pharmaceutical formulations such as branded generics and generic pharmaceuticals. The company’s portfolio includes products for the treatment of psychiatric, neurological, nephrological, gastroenterological, orthopedic and ophthalmologic diseases and disorders, and heart diseases. The company carries out product development, process chemistry, and manufacture of complex formulations, active pharmaceutical ingredients (APIs) and over-the-counter products. It offers drugs in various dosage forms such as tablets, capsules, injectables, inhalers, ointments, creams, and liquids. The company has manufacturing facilities in North America, Latin America, EMEA and Asia Pacific. Sun Pharma is headquartered in Mumbai, Maharashtra, India.
For a complete picture of Deuruxolitinib phosphate’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
